-
Bladen C.L., Salgado D., Mongeset S. et al. The TREAT-NMD DMD Global Database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015;36(4):395-402. DOI: 10.1002/humu.22758 EDN: UFQPHB
-
Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002;82(2):291-329. DOI: 10.1002/humu.22758
-
Van der Pijl E.M., van Putten M., Niks E.H. et al. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. Eur J Neurosci 2016;43(12):1623-35. DOI: 10.1111/ejn.13249
-
Tuffery-Giraud S., Béroud C., Leturcq F. et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase. Hum Mutat 2009;30(6):934-45. DOI: 10.1002/humu.20976
-
Oshima J., Magner D.B., Lee J.A. et al. Regional genomic instability predisposes to complex dystrophin gene rearrangements. Hum Genet 2009;126(3):411-23. DOI: 10.1007/s00439-009-0679-9 EDN: CIDSZD
-
Pegoraro E., Hoffman E.P., Pivaet L. et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011;76(3):219-26. DOI: 10.1212/WNL.0b013e318207afeb
-
Nowak K.J., Davies K.E. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 2004;5(9):872-6. DOI: 10.1038/sj.embor.7400221
-
Crisafulli S., Sultana J., Fontana A. et al. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. Orphanet J Rare Dis 2020;15(1):141. DOI: 10.1186/s13023-020-01430-8 EDN: JMSAJU
-
Mercuri E., Bönnemann C.G., Muntoni F. Muscular dystrophies. Lancet 2019;394(10213):2025-38. DOI: 10.1016/S0140-6736(19)32910-1
-
Landfeldt E., Thompson R., Sejersen T. et al. Life expectancy at birth in Duchenne muscular dystrophy: A systematic review and meta-analysis. Eur J Epidemiol 2020;35(7):643-53. DOI: 10.1007/s10654-020-00613-8 EDN: UPUROO
-
Nigro G., Comi L.I., Limongelli F.M. et al. Prospective study of X-linked progressive muscular dystrophy in campania. Muscle Nerve 1983;6(4):253-62. DOI: 10.1002/mus.880060403
-
Burke J.F., Mogg A.E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985;13(17):6265-72. DOI: 10.1093/nar/13.17.6265 EDN: IUBPYL
-
Martin R., Mogg A.E., Heywood L.A. et al. Aminoglycoside suppression at UAG, UAA and UGA codons in Escherichia coli and human tissue culture cells. Mol Gen Genet 989;217(2-3):411-8. DOI: 10.1007/BF02464911
-
Uis S. Gonzalez I., Spencer J.P. Aminoglycosides: A practical review. Am Fam Physician 1998;58(8):1811-20. EDN: CWIXLX
-
Rosenberg C.R., Fang X., Allison K.R. Potentiating aminoglycoside antibiotics to reduce their toxic side effects. PLoS One 2020;15(9):e0237948. DOI: 10.1371/journal.pone.0237948
-
Kimura S., Ito K., Miyagi T. et al. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy. Brain Dev 2005;27(6):400-5. DOI: 10.1016/j.braindev.2004.09.014
-
Politano L., Nigro G., Nigro V. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003;22(1):15-21.
-
Wagner K.R., Hamed S., Hadley D.W. et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49(6):706-11. DOI: 10.1002/ana.1023
-
Barton-Davis E.R., Cordier L., Shoturma D.I. et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104(4):375-81. DOI: 10.1172/JCI7866
-
Malik V., Rodino-Klapac L.R., Viollet L. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010;67(6):771-80. DOI: 10.1002/ana.22024
-
Welch E.M., Barton E.R., Zhuo J. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447(7140):87-91. DOI: 10.1038/nature05756
-
Du M., Liu X., Welch E.M. et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008;105(6):2064-9. DOI: 10.1073/pnas.0711795105
-
Finkel R.S., Flanigan K.M., Wong B. et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PloS One 2013;8(12):e81302. DOI: 10.1371/journal.pone.0081302
-
Bushby K., Finkel R., Wong B. et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014;50(4): 477-87. DOI: 10.1002/mus.24332
-
De Cacau L.A.P., de Santana-Filho V.J., Maynard L.G. et al. Reference values for the six-minute walk test in healthy children and adolescents: A systematic review. Braz J Cardiovasc Surg 2016;31(5):381-8. DOI: 10.5935/1678-9741.20160081
-
Kasović M., Štefan L., Petrić V. Normative data for the 6-min walk test in 11-14 year-olds: A population-based study: 1. BMC Pulm Med 2021;21(1):1-6. DOI: 10.1186/s12890-021-01666-5 EDN: LOWEDM
-
Henricson E., Abresch R., Han J.J. et al. The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: Longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 2013;5:ecurrents.md.9e17658b007eb79fcd6f723089f79e06. DOI: 10.1371/currents.md.9e17658b007eb79fcd6f723089f79e06
-
McDonald C.M., Campbell C., Torricelli R.E. et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Lond Engl 2017;390(10101):1489-98. DOI: 10.1016/S0140-6736(17)31611-2
-
Morkous S.S. Treatment with ataluren for Duchene muscular dystrophy. Pediatr Neurol Briefs 2020;34:12. DOI: 10.15844/pedneurbriefs-34-12